| Cynanbungeigenin C and D — Cynanbungeigenin C (CBC) and Cynanbungeigenin D (CBD) are a pair of epimeric C21 steroidal natural products isolated from Cynanchum bungei Decne. They are best classified as plant-derived small-molecule Hedgehog pathway inhibitors, with reported activity at or near the GLI transcriptional effector level rather than as canonical Smoothened-only inhibitors. The abbreviation CBC/D is preferable in this database entry because CBC and CBD also commonly refer to cannabinoids.
Primary mechanisms (ranked):
- Hedgehog pathway suppression through GLI-level blockade, reducing downstream GLI1-dependent transcriptional output.
- Suppression of Hedgehog-dependent medulloblastoma growth and tumor-propagating signaling.
- Anti-proliferative and pro-apoptotic tumor effects, strongest evidence currently from medulloblastoma models for CBC/D and colorectal cancer models for the CBC derivative CBC-1.
- Drug-development constraint: poor aqueous solubility of parent CBC, motivating CBC-1 derivative synthesis with improved solubility and stronger colorectal cancer activity.
Bioavailability / PK relevance: Human pharmacokinetics, oral bioavailability, metabolism, and clinically achievable exposure are not established. Parent CBC has reported poor water solubility; CBC-1 was developed partly to improve this limitation. Mouse in-vivo activity is preclinical and should not be treated as evidence of human exposure feasibility.
In-vitro vs systemic exposure relevance: The mechanistic evidence is concentration-driven and mostly preclinical. Because human PK data are absent, common in-vitro concentrations cannot yet be judged against achievable systemic exposure. Solubility and formulation are central translation constraints.
Clinical evidence status: Preclinical only. Evidence consists mainly of natural-product isolation, cell-based Hedgehog/GLI assays, medulloblastoma tumor models, and a newer CBC-derived GLI1 inhibitor study in colorectal cancer. No human oncology trials or regulatory approval were identified for CBC/D or CBC-1.
CBC/D Cancer Mechanism Matrix
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
GLI transcriptional output |
↓ GLI signaling |
Not established |
G |
Blocks Hedgehog signaling at the GLI level |
Core mechanism for CBC/D in Hedgehog-dependent medulloblastoma; CBC-1 derivative evidence supports direct GLI1 targeting in CRC models. |
| 2 |
Hedgehog pathway |
↓ HH pathway activity |
Not established |
G |
Suppresses oncogenic HH pathway dependence |
Most relevant where tumors depend on SHH/HH-GLI signaling; likely context-dependent across cancers. |
| 3 |
Medulloblastoma growth |
↓ proliferation and tumor growth |
Not established |
G |
Antitumor activity in HH-dependent medulloblastoma models |
Parent CBC/D evidence is strongest in this disease model rather than broad pan-cancer evidence. |
| 4 |
Apoptosis |
↑ apoptosis |
Not established |
G |
Cell death secondary to GLI1 suppression |
Best documented for CBC-1 derivative in colorectal cancer; parent CBC/D apoptosis evidence should be marked derivative-supported unless confirmed in the original paper. |
| 5 |
Tumor progression |
↓ tumor-propagating capacity |
Not established |
G |
Reduced malignant growth phenotype |
tumor cell proliferation or tumor progression suppression; external evidence supports growth suppression more clearly than migration-specific effects. |
| 6 |
ROS NRF2 Ca²⁺ Glycolysis HIF-1α |
Not established |
Not established |
G |
No primary evidence found |
Do not force redox, NRF2, calcium, glycolysis, or hypoxia axes unless a direct CBC/D paper supports them. |
| 7 |
Clinical Translation Constraint |
Solubility-limited parent compound |
Safety window not established |
G |
PK and formulation uncertainty |
Parent CBC poor water solubility and absent human PK are the main database constraints; CBC-1 derivative improves solubility but remains preclinical. |
TSF legend:
P: 0–30 min
R: 30 min–3 hr
G: >3 hr
|